- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07840196
NG004 in Incomplete Spinal Cord Injury Patients (SPROUT-2)
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Director of Clinical Research
- Numer telefonu: +41433005263
- E-mail: clinical@novagotx.com
Lokalizacje studiów
-
-
-
Bayreuth, Niemcy
- Rekrutacyjny
- Klinik für Querschnittgelähmte, Klinikum Bayreuth
-
Kontakt:
- E-mail: qs-studien@klinikum-bayreuth.de
-
Bochum, Niemcy
- Jeszcze nie rekrutacja
- BG Universitätsklinikum Bergmannsheil
-
Halle, Niemcy
- Jeszcze nie rekrutacja
- Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
-
Hamburg, Niemcy
- Jeszcze nie rekrutacja
- BG Klinikum Hamburg
-
Heidelberg, Niemcy
- Rekrutacyjny
- Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
-
Kontakt:
- E-mail: NISCI.OUK@med.uni-heidelberg.de
-
Murnau am Staffelsee, Niemcy
- Rekrutacyjny
- Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
-
Kontakt:
- E-mail: MNU_SPROUT@bgu-murnau.de
-
Tübingen, Niemcy
- Rekrutacyjny
- BG Klinik Tübingen
-
Kontakt:
- E-mail: SPROUT@bgu-tuebingen.de
-
-
-
-
-
Basel, Szwajcaria
- Rekrutacyjny
- REHAB Basel
-
Kontakt:
- E-mail: sprout-Studienteam@rehab.ch
-
Nottwil, Szwajcaria
- Rekrutacyjny
- Swiss Paraplegic Centre
-
Kontakt:
- E-mail: sprout@paraplegie.ch
-
Zurich, Szwajcaria
- Rekrutacyjny
- Universitätsklinik Balgrist
-
Kontakt:
- E-mail: sprout@balgrist.ch
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening
- 4-28 days post-injury and no earlier than 4 days after spinal surgery
- No required mechanical ventilation or patients that do not completely depend on mechanical ventilation
- Hemodynamically and clinical stable patient according to the acute SCI condition at baseline
Exclusion Criteria:
- Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
- Multiple levels of clinically relevant spinal cord lesions
- Major brachial or lumbar plexus damage/trauma
- Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
- Other significant pre-existing or current severe systemic disease
- History of or an episode of multiple sclerosis or Guillain-Barre syndrome
- History of recent meningitis or meningoencephalitis
- History of refractory epilepsy
- Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
- Presence of any unstable medical or psychiatric condition
- Drug dependence any time within the last 6 months before Screening
- Pregnant or nursing women
- History of a life-threatening allergic or immune-mediated reaction
- Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
- Patients who are unconscious
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Komparator placebo: Placebo
|
repeated intrathecal injections of Placebo within 30 days |
|
Eksperymentalny: NG004
|
repeated intrathecal injections of NG004 within 30 days |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Rodzaj, częstotliwość, nasilenie i związek przyczynowy zdarzeń niepożądanych (AES), poważnych reakcji AE i niepożądanych leków
Ramy czasowe: Od rozpoczęcia leczenia do 6 miesięcy
|
Od rozpoczęcia leczenia do 6 miesięcy
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
NG004 concentration in serum and CSF
Ramy czasowe: From treatment start up to 6 months
|
From treatment start up to 6 months
|
|
|
Effect on neurological recovery according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol as change in ISNCSCI upper extremities motor score (UEMS) and Integrated Neurological Change Score
Ramy czasowe: Baseline to 6 months
|
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery |
Baseline to 6 months
|
|
Effect on daily life functioning as Spinal Cord Independence Measure (SCIM-III)
Ramy czasowe: Month 6
|
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities. |
Month 6
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Effect on Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP): strength and prehension performance
Ramy czasowe: Month 6
|
The GRASSP is a validated clinical measure of hand function in tetraplegic patients and can assess changes in impairment over time. The GRASSP (Version 2) consists of 4 subtests. The subtest strength (manual muscle testing of 10 muscles of the upper limb) and the subtest prehension performance (grasping test with 4 activities of daily living) will be performed. |
Month 6
|
|
Effect on the Walking Index for Spinal Cord Injury (WISCI II)
Ramy czasowe: Month 6
|
WISCI II is a 21-item hierarchical scale of walking based on physical assistance, need of braces and devices, with an ordinal range from 0 (unable to walk) to 20 (walking without assistance for at least 10 meters). |
Month 6
|
|
Effect on 10-meter walking test (10mWT)
Ramy czasowe: Month 6
|
10mWT is a quantitative measurement of lower extremity function. The patient shall walk a set distance (10 meters) at preferred walking speed. The distance covered, the time taken, and the assistance used will be recorded. |
Month 6
|
|
Effect on 6-minute walking test (6MWT)
Ramy czasowe: Month 6
|
6MWT is a test used to determine the locomotor performance. Patients are instructed to walk as far as possible during 6 minutes, with rests being taken whenever required. The distance covered in time or until abort, the walking time until abort, and the number of rests are assessed. |
Month 6
|
|
Effect on respiratory function: Forced Vital Capacity (FVC) and Forced Expiratory volume in one second (FEV1)
Ramy czasowe: Baseline up to 6 months
|
The various lung parameters will include Forced Vital Capacity (FVC), Forced Expiratory volume in one second (FEV1) and peak expiratory flow (PEF). FVC measures volume in Litter delivered during an expiration made as forcefully and completely as possible starting from full inspiration. FEV1 assess the volume measured in Litter delivered in the first second of a FVC maneuver. PEF measures highest flow delivered during FVC maneuver (L/min). |
Baseline up to 6 months
|
|
Effect on respiratory function: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]
Ramy czasowe: Baseline up to 6 months
|
Effect on respiratory function measuring respiratory muscle strength: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]. MIP is assessed as the pressure (in cmH2O) during inhalation against a completely occluded airway and is used to evaluate inspiratory muscle strength. MEP a measure of the strength of expiratory muscles, obtained by having the patient exhale as strongly as possible against a resistance. It is assessed as the pressure (in cmH2O) during exhaling. |
Baseline up to 6 months
|
|
Effect on spinal cord morphology, lesion size, and tissue integrity using magnetic resonance imaging (MRI) scans
Ramy czasowe: Baseline to 6 months
|
MRI scans of the spine will be used to characterize the extent of the lesion from the SCI by assessing morphological measures. Analyses of lesion parameters as preserved tissue bridges, lesion volume, lesion length, lesion width and spinal cord atrophy will be performed. Spinal cord atrophy is measured by calculating the cross-sectional area (CSA) of the spinal cord. Quantitative MRI will be used to assess microstructural tissue integrity, as assed by diffusion tensor imaging and quantitative magnetization transfer saturation mapping. |
Baseline to 6 months
|
|
Effect on muscle spasticity (Modified Ashworth Scale [MAS])
Ramy czasowe: Month 6
|
MAS is a 6-point muscle tone assessment scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity or increased resistance to passive movement. |
Month 6
|
|
Effect on neuropathic pain (EMSCI Neuropathic Pain Assessment Form [NePAF])
Ramy czasowe: Month 6
|
Neuropathic pain will be assessed by the European Multicenter Study About Spinal Cord Injury (EMSCI) Neuropathic Pain Assessment Form (NePAF), which is based on a structured interview using rating scales, and includes specific assessment of the SCI-associated neuropathic pain in terms of location, quality and severity. The pain intensity is rated with an 11-point numeric rating scale with 0 indicating no pain and 10 indicating the worst imaginable pain. |
Month 6
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- NG004-SCI-002
- 2026-526089-26 (Numer EudraCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .